Johnson & Johnson Q3 net earnings fall 96% to $210 million; sales rise 6% to $25.4 billion
PUBT · 1d ago
Share
Listen to the news
- Johnson & Johnson posted Q3 2026 net earnings of USD 210 million, swinging from profit a year earlier.
- Reported sales rose 6% to USD 25.4 billion versus Q3 2025.
- Innovative Medicine net sales climbed 8% to USD 16.76 billion, while MedTech net sales increased to USD 8.64 billion.
- CEO Joaquín Duato cited “accelerating momentum” and highlighted OTTAVA progress and positive Phase 3 multiple myeloma results.
- 2026 reported sales guidance increased to USD 101.0 billion–USD 101.4 billion, with adjusted EPS guidance lifted to USD 11.05–USD 11.15.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013290017) on October 13, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending